📰 Solid Tumors News

Page 44 - Solid Tumors News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

June 6, 2022

Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid

United States Farletuzumab Ecteribulin Morab Ishin Nishio Eisai Co Ltd Department Of Obstetrics American Society Of Clinical Oncology

Source: finanznachrichten.de

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

June 5, 2022

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United States New Zealand Farletuzumab Ecteribulin Morab Michele Randazzo Prnewswire Eisai Ishin Nishio

Source: apnews.com

EMD Serono Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways | Small Molecules

June 4, 2022

EMD Serono Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

United States Vertex Pharmaceuticals Gilead Sciences Serono Inc American Association For Cancer Research Annual Meeting Merck Kga

Source: pipelinereview.com

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients

June 4, 2022

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results...

United States South Korea College Of American Pathologists American Society Of Clinical Oncology Gilead Sciences Inc Gilead Sciences

Source: prnewswire.com

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

June 4, 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

United States University Of California San Francisco Foster City Jacquie Ross Gilead Sciences American Society Of Clinical Oncology

Source: apnews.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

June 3, 2022

New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head and neck cancer and advanced bladder

United States Noelle Piscitelli Vertex Pharmaceuticals Gilead Sciences European Commission Drug Administration

Source: finanznachrichten.de

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

June 3, 2022

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors Patients Receiving a Dose...

United States Edna Kaplan Merck Sharpe Dohme Lewish Bender Jacob Stephen Thomas Michael Miller

Source: prnewswire.com

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas

June 2, 2022

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Sarcomas In a Heavily Pre-Treated,...

United States Edna Kaplan Merck Sharpe Dohme Lewish Bender Michael Miller Bristol Myers Squibb

Source: prnewswire.com